[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 498
Citations 0
Comment & Response
September 17, 2019

Catheter Ablation Compared With Drug Therapy for Atrial Fibrillation—Reply

Author Affiliations
  • 1Mayo Clinic, Rochester, Minnesota
  • 2Duke University, Durham, North Carolina
  • 3Duke Clinical Research Institute, Durham, North Carolina
JAMA. 2019;322(11):1106. doi:10.1001/jama.2019.10688

In Reply Dr Lucijanic and colleagues express concern about the proportion of patients randomized to the drug group of the trial who crossed over to receive an ablation, and the biases those crossovers may have introduced in the analysis. As noted in the publication,1 there were also crossovers among patients randomized to the ablation group, namely patients who did not undergo the ablation after being randomized. This could also have introduced bias. Our concern about crossovers in either direction and biases introduced by the crossovers was precisely why prespecified sensitivity analyses (as-treated and per-protocol analyses) were performed and reported1 and discussed in the online Supplement 3. The crossover of patients in the drug group to receive an ablation was primarily symptom-driven and due to the fact that drug options for treating the symptoms had been exhausted. The reasons some patients in the ablation group never underwent ablation were primarily because of patient or family refusal.